
Ryan Dorton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11402922/publications.pdf Version: 2024-02-01



Ργλη Πορτον

#	Article	IF	CITATIONS
1	Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate. Cancer Research, 2007, 67, 4434-4442.	0.9	161
2	Preclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate. Molecular Pharmaceutics, 2007, 4, 659-667.	4.6	100
3	Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue. Cancer Research, 2008, 68, 9839-9844.	0.9	86
4	Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 918-925.	2.5	65
5	In Vivo Structural Activity and Optimization Studies of Folateâ^'Tubulysin Conjugates. Molecular Pharmaceutics, 2009, 6, 1518-1525.	4.6	60
6	Folate–Vinca Alkaloid Conjugates for Cancer Therapy: A Structure–Activity Relationship. Bioconjugate Chemistry, 2014, 25, 560-568.	3.6	50
7	Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 336-343.	2.5	42
8	Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic. Scientific Reports, 2018, 8, 8943.	3.3	40
9	Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs. Clinical Cancer Research, 2014, 20, 2104-2114.	7.0	24
10	Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate. Bioconjugate Chemistry, 2019, 30, 1805-1813.	3.6	22
11	High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. Molecular Cancer Therapeutics, 2016, 15, 1998-2008.	4.1	13
12	Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy. Cancer Chemotherapy and Pharmacology, 2017, 79, 1151-1160.	2.3	10
13	Abstract 832: Pre-clinical development of EC1456: A potent Folate targeted Tubulysin SMDC. Cancer Research, 2014, 74, 832-832.	0.9	6